by Christina | Jul 9, 2024 | Uncategorized
Scott Beardsley is the Managing Partner for the Venture Investments team of Novo Holdings. He joined Novo Ventures (US) Inc. in San Francisco, California, in 2012. From 2009-2012, Mr. Beardsley was a Senior Partner with Novo A/S’ Growth Equity team in Copenhagen,...
by Christina | Jul 22, 2024 | Uncategorized
Ari Brettman is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December 2018. Dr. Brettman joined Clarus in September 2014. Dr. Brettman is focused on investments across the firm’s...
by Christina | Jul 22, 2024 | Uncategorized
Ray Camahort is a Partner at Novo Holdings Venture Investments. He has over 15 years of combined investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing. Prior to joining Novo Ventures, Dr. Camahort worked in...
by Christina | Jul 22, 2024 | Uncategorized
Nicholas Galakatos is the Global Head of Life Sciences and is the Chairman of its Investment Committees, having joined Blackstone as part of its acquisition of Clarus in December 2018. Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing...
by Christina | Jul 22, 2024 | Uncategorized
Before joining Anthos Therapeutics, Bill Meury served as President and Chief Executive Officer of the Boston-based neuroscience company Karuna Therapeutics, where he led the company through a period of rapid expansion, and a transition to a fully integrated R&D...
